Trimel Pharmaceuticals Corporation is a Canada-based development-stage specialty pharmaceutical company. It is engaged in developing medications for male hypogonadism, female sexual dysfunction and respiratory disorders. It holds the development and marketing rights to a bioadhesive intranasal gel drug delivery technology platform and a dry power inhaler, TriVair. Its products include Natesto, Tefina, Estrace and CompleoTRT. Natesto is a testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Tefina is an intranasal, low-dose gel formulation of testosterone, which is being developed as a use as required treatment option for women experiencing Female Orgasmic Disorder. Estrace containing 17 Beta-estradiol, is indicated for symptomatic relief of menopausal symptoms and prevention of osteoporosis. The Company is also developing CompleoTRT for the treatment of male hypogonadism.